top of page
Recent Research
JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis
With JNJ2113's (icotrokinra) upcoming ulcerative colitis ANTHEM-UC trial reading out this first quarter, our unique UC specific analysis...
Feb 11
JNJ/PTGX: JNJ2113: Oral dosing faces hurdles of new rival classes in psoriasis & Ulcerative Colitis
The injectable IL23 class has been successful in treating a wide variety of inflammatory conditions such as psoriasis and inflammatory...
Sep 18, 2023
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page